These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 28083070)

  • 21. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist.
    Butler DM; Maini RN; Feldmann M; Brennan FM
    Eur Cytokine Netw; 1995; 6(4):225-30. PubMed ID: 8789287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emerging drugs for asthma.
    Walsh GM
    Expert Opin Emerg Drugs; 2008 Dec; 13(4):643-53. PubMed ID: 19046132
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aptamers Against Pro- and Anti-Inflammatory Cytokines: A Review.
    Boshtam M; Asgary S; Kouhpayeh S; Shariati L; Khanahmad H
    Inflammation; 2017 Feb; 40(1):340-349. PubMed ID: 27878687
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alterations of the mucosal immune system in inflammatory bowel disease.
    MacDermott RP
    J Gastroenterol; 1996 Dec; 31(6):907-16. PubMed ID: 9027661
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biologic therapies against inflammatory bowel disease: a dysregulated immune system and the cross talk with gastrointestinal mucosa hold the key.
    Dharmani P; Chadee K
    Curr Mol Pharmacol; 2008 Nov; 1(3):195-212. PubMed ID: 20021434
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Infections in patients with rheumatoid arthritis receiving anti-cytokine therapy: biological mechanisms and clinical aspects].
    Botsios C; Ostuni P; Sfriso P; Furlan A; Fiocco U; Sgarabotto D; Todesco S
    Reumatismo; 2003; 55(4):224-35. PubMed ID: 14872221
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytokine and anti-cytokine therapies for inflammatory bowel disease.
    Ogata H; Hibi T
    Curr Pharm Des; 2003; 9(14):1107-13. PubMed ID: 12769750
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biological response modifiers in the management of rheumatoid arthritis.
    Louie SG; Park B; Yoon H
    Am J Health Syst Pharm; 2003 Feb; 60(4):346-55. PubMed ID: 12625216
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-inflammatory cytokines and cytokine antagonists.
    Standiford TJ
    Curr Pharm Des; 2000 Apr; 6(6):633-49. PubMed ID: 10788601
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inflammatory Kinetics and Efficacy of Anti-inflammatory Treatments on Human Nucleus Pulposus Cells.
    Walter BA; Purmessur D; Likhitpanichkul M; Weinberg A; Cho SK; Qureshi SA; Hecht AC; Iatridis JC
    Spine (Phila Pa 1976); 2015 Jul; 40(13):955-63. PubMed ID: 25893355
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.
    Yao X; Huang J; Zhong H; Shen N; Faggioni R; Fung M; Yao Y
    Pharmacol Ther; 2014 Feb; 141(2):125-39. PubMed ID: 24076269
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [New drugs and treatment strategies for rheumatoid arthritis].
    Fantini F
    Recenti Prog Med; 2003 Sep; 94(9):361-79. PubMed ID: 12942798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Important role of proinflammatory cytokines/other endogenous substances in drug-induced hepatotoxicity: depression of drug metabolism during infections/inflammation states, and genetic polymorphisms of drug-metabolizing enzymes/cytokines may markedly contribute to this pathology.
    Prandota J
    Am J Ther; 2005; 12(3):254-61. PubMed ID: 15891270
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is TGFβ as an anti-inflammatory cytokine required for differentiation of inflammatory T
    Pourgholaminejad A; Aghdami N; Baharvand H; Moazzeni SM
    J Immunotoxicol; 2016 Nov; 13(6):775-783. PubMed ID: 27754729
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases.
    Toussirot E
    Inflamm Allergy Drug Targets; 2012 Apr; 11(2):159-68. PubMed ID: 22280236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IL-1 family cytokines in chronic inflammatory disorders.
    Stříž I
    Vnitr Lek; 2019; 65(2):81-85. PubMed ID: 30909697
    [TBL] [Abstract][Full Text] [Related]  

  • 37. From cellular receptors to transduction-transcription pathways for cytokines: at which level should the inhibition be targeted in inflammation?
    Dayer JM; Molnarfi N; Burger D
    Expert Opin Biol Ther; 2005 Sep; 5 Suppl 1():S83-96. PubMed ID: 16187943
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Juvenile rheumatoid arthritis: therapeutic perspectives.
    Chikanza IC
    Paediatr Drugs; 2002; 4(5):335-48. PubMed ID: 11994038
    [TBL] [Abstract][Full Text] [Related]  

  • 39. VHH-Based Bispecific Antibodies Targeting Cytokine Production.
    Nosenko MA; Atretkhany KN; Mokhonov VV; Efimov GA; Kruglov AA; Tillib SV; Drutskaya MS; Nedospasov SA
    Front Immunol; 2017; 8():1073. PubMed ID: 28919896
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interleukin-1 and interleukin-1 receptor antagonist.
    Dinarello CA
    Nutrition; 1995; 11(5 Suppl):492-4. PubMed ID: 8748206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.